[8-K] Q32 Bio Inc. Reports Material Event

Rhea-AI Filing Summary

Q32 Bio (NASDAQ:QTTB) announced the resignation of Chief Medical Officer Jason Campagna, M.D., Ph.D., effective July 9, 2025. The company has appointed Adrien Sipos, M.D., Ph.D. as Interim Chief Medical Officer, effective the same date. This Form 8-K filing discloses the leadership transition in the company's medical division.

Insights

Corporate Governance Expert

Unexpected CMO departure and interim replacement signals potential shift in clinical development strategy.

The abrupt nature of the CMO transition, with only a 19-day notice period between announcement and effective date, raises governance concerns. While the appointment of Dr. Sipos as Interim CMO provides continuity, the 'interim' designation suggests the company may conduct a broader executive search. This transition period could impact ongoing clinical programs and regulatory interactions.

NASDAQ false 0001661998 0001661998 2025-06-20 2025-06-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2025

Q32 Bio Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38433		47-3468154
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
830 Winter Street
Waltham, Massachusetts				02451
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 781 999-0232

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		QTTB		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 20, 2025, Jason Campagna, M.D., Ph.D. resigned from his role as Chief Medical Officer of Q32 Bio Inc. (the “Company”), effective as of July 9, 2025. Adrien Sipos, M.D., Ph.D. has been appointed by the Company as its Interim Chief Medical Officer, effective as of July 9, 2025.

Item 7.01 Regulation FD Disclosure.

On June 25, 2025, the Company issued a press release announcing the foregoing leadership transition. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued on June 25, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Q32 BIO INC.
Date: June 25, 2025				By:		/s/ Jodie Morrison
				Name: Title:		Jodie Morrison Chief Executive Officer